

In the Claims:

1-26. (Cancelled)

27. (Previously presented) A method of treating a neoplastic cell, comprising:
administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

28. (Original) The method of claim 27 wherein expression of the human MDM2 gene is inhibited by administering antisense oligonucleotides.

29. (Previously presented) A method of treating a neoplastic cell, comprising:
administering into the cell triple-strand forming oligonucleotides which bind to and are complementary to a human MDM2 gene and which inhibit transcription or translation of the human MDM2 gene.

30-55. (Cancelled)

56. (Previously presented) A method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

57. (Previously presented) A method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell triple-strand forming oligonucleotides which bind to and are complementary to a human MDM2 gene and which inhibit transcription or translation of the human MDM2 gene.

58. (Previously presented) The method of claim 27 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

59. (Previously presented) The method of claim 29 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

60. (Previously presented) The method of claim 56 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

61. (Previously presented) The method of claim 57 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.